Applied Therapeutics, Inc. — Director's Dealing 2022

Aug 5, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Applied Therapeutics Inc. (APLT)
CIK: 0001697532
Period of Report: 2022-08-02

Reporting Person: Shendelman Shoshana (Director, President and CEO, 10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-08-02	Employee Stock Option (Right to Buy)	$3.33	D	234616	Disposed	2032-01-25	Common Stock (234616)	Direct
2022-08-02	Employee Stock Option (Right to Buy)	$1.05	D	234616	Acquired	2032-01-25	Common Stock (234616)	Direct
2022-08-02	Employee Stock Option (Right to Buy)	$23.15	D	101670	Disposed	2030-12-10	Common Stock (101670)	Direct
2022-08-02	Employee Stock Option (Right to Buy)	$1.05	D	101670	Acquired	2030-12-10	Common Stock (101670)	Direct
2022-08-02	Employee Stock Option (Right to Buy)	$22.20	D	134979	Disposed	2029-12-16	Common Stock (134979)	Direct
2022-08-02	Employee Stock Option (Right to Buy)	$1.05	D	134979	Acquired	2029-12-16	Common Stock (134979)	Direct
2022-08-02	Employee Stock Option (Right to Buy)	$22.20	D	23317	Disposed	2029-12-16	Common Stock (23317)	Direct
2022-08-02	Employee Stock Option (Right to Buy)	$1.05	D	23317	Acquired	2029-12-16	Common Stock (23317)	Direct
2022-08-02	Employee Stock Option (Right to Buy)	$10.00	D	607484	Disposed	2029-05-12	Common Stock (607484)	Direct
2022-08-02	Employee Stock Option (Right to Buy)	$1.05	D	607484	Acquired	2029-05-12	Common Stock (607484)	Direct

Footnotes

F1: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options.

F2: These Options are fully vested.

F3: Reflects an initial grant of 256,850 Options granted on December 10, 2020 that vests as follows: One-fourth (1/4th) of the shares subject to the Option shall vest on December 10, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to provide services through each such date.

F4: Reflects an initial grant of 209,000 Options granted on December 16, 2019 that vests as follows: One-fourth (1/4th) of the shares subject to the Option shall vest on December 16, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to provide services through each such date.

F5: Reflects an initial grant of 767,349 Options granted on May 13, 2019 that vests as follows: One-fourth (1/4th) of the shares subject to the Option shall vest on May 13, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.